The novel tRNA-derived fragment, tiRNA-Met, inhibits the malignant progression of triple-negative breast cancer by regulating RANBP3L via a targeted interaction with SNRPA
Our study identified tiRNA-Met as a novel anti-oncogenic tRF and elucidated its mechanism for inhibiting the malignancy of TNBC. tiRNA-Met directly bound to SNRPA, promoting its degradation and stabilizing RANBP3L mRNA, ultimately leading to the inhibition of the mTORC1 signaling pathway. These findings position tiRNA-Met as a promising candidate for diagnostic and therapeutic applications in TNBC.
Authors
- Jingjing Lu (ORCID: https://orcid.org/0000-0003-3831-5537)
- Wen Zhu (ORCID: https://orcid.org/0000-0003-0832-2453)
- Ping Zhou (ORCID: https://orcid.org/0000-0002-4183-0639)
- Ping Zhu (ORCID: https://orcid.org/0000-0001-9490-9503)
- Bujie Xu
- Yangbai Sun (ORCID: https://orcid.org/0000-0002-2853-2813)
- Xiufen Zhang (ORCID: https://orcid.org/0000-0002-7959-2453)
- Xue Chao Wang (ORCID: https://orcid.org/0000-0002-2381-9145)
- Linzi Zeng
Institutions
- Shanghai Medical College of Fudan University (CN)
- Nantong University (CN)
- Fudan University (CN)
- Ruijin Hospital (CN)
- Affiliated Hospital of Nantong University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Wuxi Fourth People's Hospital (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Cellular & Molecular Biology Letters
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1186/s11658-025-00738-2
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation